Becton, Dickinson and Company $BDX Shares Bought by Versor Investments LP

Versor Investments LP grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 73.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,336 shares of the medical instruments supplier’s stock after purchasing an additional 1,833 shares during the period. Versor Investments LP’s holdings in Becton, Dickinson and Company were worth $747,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 3.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier’s stock worth $2,880,510,000 after purchasing an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after purchasing an additional 667,957 shares during the period. JPMorgan Chase & Co. increased its position in Becton, Dickinson and Company by 7.6% during the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier’s stock worth $1,012,649,000 after purchasing an additional 312,124 shares during the period. Finally, Nordea Investment Management AB increased its position in Becton, Dickinson and Company by 0.4% during the 2nd quarter. Nordea Investment Management AB now owns 3,365,509 shares of the medical instruments supplier’s stock worth $577,420,000 after purchasing an additional 12,602 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 1,895 shares of company stock worth $358,995. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $177.20 on Tuesday. The business’s fifty day moving average price is $188.03 and its two-hundred day moving average price is $182.77. The stock has a market cap of $50.79 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BDX shares. Argus upped their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley upped their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler restated a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.